



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/511,414
Filing Date	14 October 2004
First Named Inventor	David P. BINGAMAN et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2380 US F

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
K	A1	US- 2002/0037929 A1	03/28/2002	Kapin et al.	
K	A2	US- 4,045,576	08/30/1977	Welstead Jr. et al.	
K	A3	US- 4,126,635	11/21/1978	Welstead Jr. et al.	
K	A4	US- 4,254,146	03/03/1981	Walsh	
K	A5	US- 4,313,949	02/02/1982	Shanklin Jr. et al.	
K	A6	US- 4,503,073	03/05/1985	Walsh et al.	
K	A7	US- 4,568,695	02/04/1986	Moran et al.	
K	A8	US- 4,683,242	07/28/1987	Poser	
K	A9	US- 4,910,225	03/20/1990	Ogawa et al.	
K	A10	US- 5,475,034	12/12/1995	Yanni et al.	
K	A11	US- 6,066,671	05/23/2000	Yanni et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
K	A12	UK 2,071,086 A	09/16/1981	Welstead et al.		
K	A13	UK 2,093,027 A	08/25/1982	Walsh et al.		
K	A14	WO 01/15744 A1	03/08/2001	Brigham et al.		
K	A15	WO 02/078681 A2	10/10/2002	Alcon, Inc.		

Examiner  
SignatureDate  
Considered

10/04/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/511,414
				Filing Date	14 October 2004
				First Named Inventor	David P. BINGAMAN et al.
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2380 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
K	B1	Bingaman DP, et al., "Topical Ocular Delivery of Nepafenac Inhibits Preretinal Neovascularization", Abstract No. 3920 Annual Meeting of the Association For Research in Vision and Ophthalmology; Fort Lauderdale, FL (May 5-10, 2002) [XP002247861]	
K	B2	Kwak N, et al., "VEGF Is Major Stimulator in Model of Choroidal Neovascularization", IOVS 41(10):3158-3164 (2000)	
K	B3	Penn JS et al., abstract, "Studies of the Effect and Mechanism of Action of Topical Nepafenac in a Rat Model of ROP", Abstract No. 2741 Annual Meeting of the Association For Research in Vision and Ophthalmology; Fort Lauderdale, FL (May 5-10, 2002) [XP002247860]	
K	B4	Takahashi et al., "Topical Nepafenac Inhibits Ocular Neovascularization", IOVS 44(1):409-415 (2003)	
K	B5	Walsh et al., "Antiinflammatory Agents. 4.1 Syntheses and Biological Evaluation of Potential Prodrugs of 2-Amino-3-benzoylbenzeneacetic Acid and 2-Amino-3-(4-chlorobenzoyl)benzeneacetic Acid", J. Med Chem, 33:2296-2304 (1990)	
	B6		
	B7		
	B8		
	B9		
	B10		

Examiner Signature	<i>Sto. H. K.</i>	Date Considered	<i>10/4/05</i>
--------------------	-------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.